Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
about
U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathwayStructure and unfolding of the third type III domain from human fibronectinThe anti-angiogenic peptide anginex disrupts the cell membrane.Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds.Transient opening of fibronectin type III (FNIII) domains: the interaction of the third FNIII domain of FN with anastellin.Angiostatic peptides use plasma fibronectin to home to angiogenic vasculatureConformational remodeling of the fibronectin matrix selectively regulates VEGF signaling.The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts.A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived.CLT1 targets angiogenic endothelium through CLIC1 and fibronectin.New insights into form and function of fibronectin splice variants.Dynamic structure of plasma fibronectin.Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling.Vitronectin--master controller or micromanager?Matricryptins and matrikines: biologically active fragments of the extracellular matrix.Translational control plays a prominent role in the hepatocytic differentiation of HepaRG liver progenitor cells.The Interaction between the Third Type III Domain from Fibronectin and Anastellin Involves β-Strand Exchange.Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis.Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.Domain unfolding plays a role in superfibronectin formation.
P2860
Q24811943-926B5D2C-C9E6-44CA-942F-C9468F2779B1Q28506529-0041355B-BCC2-47B8-92CA-EB11AFA714A6Q28821372-B6A38E23-6D2C-4515-80C3-696F9C77BE8FQ30159968-5C14EEDB-CF45-47AD-85F6-A560664734C7Q30807745-CD48A1B6-3197-4A60-AFDF-A977781C9472Q30859990-7F851544-CFE6-42D6-8ECC-171B19778FD4Q33837087-E54BF77B-4DD6-42FA-B936-3D323BF053F5Q34112722-E5CF2410-4E87-4733-87F2-ED095B861264Q34298918-289A5FDD-F86F-4C7B-9C4E-62CDEECFE4C2Q34581273-E8B2D184-341D-47C6-850B-FF01C994FC06Q35872325-FF072405-2FB8-43E6-A42A-8A6F94A360F8Q36240084-F63E4FD8-E378-4B26-B05D-98A33BCEA7DDQ37057966-B100904C-C9BE-4A57-8CA4-34435EB365BDQ37135504-B424A078-FEBD-49C1-9D8E-1E1246C16388Q38137030-1E9A77E2-E154-4F77-B90F-F2B7F976F063Q38210749-C3E47BAE-2C3C-41D4-BF97-F894BFD3285AQ38610703-3A201584-A629-46D8-9CB0-0631B86A51F6Q38618635-EFE816CA-FD3D-4FCC-B74C-431D6DEED96DQ38927838-6C57C7CE-6113-4E5B-BCEF-62FAB546D61CQ40414210-5894C172-DA0C-4985-BA91-72611B93A660Q53749618-348D2B22-F4BD-449C-91FD-6D0E9D86EEAB
P2860
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@ast
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@en
type
label
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@ast
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@en
prefLabel
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@ast
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@en
P2860
P356
P1476
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
@en
P2093
P2860
P304
11435-11438
P356
10.1073/PNAS.1635112100
P407
P577
2003-09-17T00:00:00Z